Serological Testing for COVID-19 (SARS-CoV-2) in ESKD (NCT04378686) | Clinical Trial Compass
CompletedNot Applicable
Serological Testing for COVID-19 (SARS-CoV-2) in ESKD
Belgium500 participantsStarted 2020-04-23
Plain-language summary
Starting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing.
We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with end-stage kidney disease (ESKD) receiving renal replacement therapy
* Age 18 years or older
* Treated at University Hospitals Leuven, or Jessa Ziekenhuis Hasselt
* Providing informed consent
Exclusion Criteria:
* Refusal to provide informed consent
* Transfer to another dialysis unit
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is already completed, would my doctor be able to share or access any findings about how patients with end-stage kidney disease on dialysis developed antibodies against SARS-CoV-2, and what that might mean for my care?
2Because people with end-stage renal failure on dialysis may have a different immune response to COVID-19, should I be getting any specific antibody testing to understand my level of protection, based on what studies like this one have found?
3Given that this study focused on serological — meaning blood antibody — testing in dialysis patients, does my doctor think my current COVID-19 vaccination or infection history has given me adequate antibody protection, considering my kidney condition?
4Are there any follow-up studies or current trials building on this research that my doctor thinks might be relevant to my situation as a dialysis patient?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.